The global cardiovascular drugs market sustained modest growth over the past five years and is anticipated to continue the same over 2012-2017 and reach an estimated $174.8 billion by 2017.
Lucintel, a leading global management consulting and market research firm, has analyzed the global cardiovascular drugs industry and offers its findings in its research report, “Global Cardiovascular Drugs market 2012-2017: Trend, Profit, and Forecast Analysis.”
The industry is consolidated and affected by government regulations in different regions and countries. The global market is geographically segmented into North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW). During 2006-2011, APAC led the industry in growth and is expected to retain that position through 2017because of economic expansion, increased personal income, improved public healthcare, and longer life expectancies. Currently, North American dominates the industry. China and India are the fastest-growing cardiovascular drugs markets.
Lucintel has identified increasing regulatory interference, increasing export barriers, and shift toward lower-price generic drugs as challenges. Increasing healthcare expenditures and awareness, advances in medical technologies, and rising per capita income are industry growth stimulators.
Increase in middle class population, changing demographic profile, increase in medical insurance coverage, growing economy, and rising GDP per capita are expected to drive demand for cardiovascular drugs in APAC, providing opportunities to industry players.
The report includes manufacturers and distributors of cardiovascular drugs. This market report is an indispensable reference guide for materials suppliers, product manufacturers, investors, executives, distributors, and others that operate in this market. For business, investment, and strategic decisions, the timely, useful information in this market report can help fulfill these core needs.
Lucintel’s research report provides recent industry scope and overview, global macroeconomic overview, relative market attractiveness by region, annual industry trends,
emerging trends, and industry forecasts. In addition, the report presents a Porter's Five Forces Analysis, information about product launches and merger and acquisitions during last five years tha
t determine regional and segment opportunities, competitive landscape, and profitability trend and analysis of major industry players. The key insights sections portray beneficial information about an industry segment's growth and regional growth trends.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the market’s potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global cardiovascular drugs industry. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of cardiovascular drugs market report are:
• Industry size estimates in terms of (US $) value by regions and by segment
• Global cardiovascular drugs industry annual trend (2006-2011) and forecast (2012-2017)
• Porter’s Five Force analysis
• New product launch and merger and acquisition activity in global cardiovascular drugs insurance market
• Quarterly demand trend (Q1 2010-Q4 2011)and forecast analysis (Q1 2012 – Q4 2012) for global cardiovascular drugs market
• Gross and net profit trends in the global cardiovascular drugs market
• Cost structure trend in the global as well as regional global motor cardiovascular drugs market
• More than 45valuable figures/charts and 12 tables are provided in cardiovascular drugs market report